Celcuity posts Q4 net loss $36.7M, cash $235M, key trial data anticipated in 2025

Celcuity Inc.

Q4 net loss $36.7M ($0.85/share) vs $18.8M ($0.65/share) in Q4 2023; full year net loss $111.8M ($2.83/share).
Cash, cash equivalents and short-term investments of $235.1M at Dec 31, 2024, expected to fund operations through 2026.
PIK3CA wild-type cohort of VIKTORIA-1 Phase 3 topline data expected Q2 2025; mutant cohort data in Q4 2025.
VIKTORIA-2 Phase 3 first patient enrollment on track for Q2 2025; Phase 1b/2 mCRPC data expected late Q2 2025.
R&D expenses increased to $33.5M in Q4 from $18.1M, driven by ongoing and new clinical trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.